CAR T‐cell therapy for pancreatic cancer

Chimeric antigen receptor (CAR) T‐cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenv...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology Vol. 116; no. 1; pp. 63 - 74
Main Authors: DeSelm, Carl J., Tano, Zachary E., Varghese, Anna M., Adusumilli, Prasad S.
Format: Journal Article
Language:English
Published: United States Wiley Subscription Services, Inc 01.07.2017
Subjects:
adoptive cell therapy
Antigens, Neoplasm - immunology
Cancer surgery
CAR T cells
Carcinoembryonic Antigen - immunology
CD24 Antigen - immunology
checkpoint blockade
chimeric antigen receptor
Clinical Trials as Topic
GPI-Linked Proteins - immunology
Humans
immunotherapy
Immunotherapy, Adoptive
Mesothelin
Mucin-1 - immunology
Neoplasm Proteins - immunology
Pancreatic cancer
Pancreatic Neoplasms - immunology
Pancreatic Neoplasms - therapy
Receptor, ErbB-2 - immunology
Receptors, Antigen, T-Cell
Receptors, Natural Killer Cell - immunology
Stromal Cells - immunology
T-Lymphocytes - immunology
T-Lymphocytes - transplantation
Transplantation Conditioning
checkpoint blockade
chimeric antigen receptor
CAR T cells
adoptive cell therapy
immunotherapy
ISSN:0022-4790, 1096-9098, 1096-9098
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chimeric antigen receptor (CAR) T‐cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T‐cell therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0022-4790
1096-9098
1096-9098
DOI:10.1002/jso.24627